Properties of Two While-Alive Estimands for Recurrent Events and Their Potential Estimators

References

• Akacha, M., Binkowitz, B., Bretz, D., Fritsch, A., Hougaard, P., Jahn-Eimermacher, A., Mendolia, F., Ravn,H., Roger, J., Schlömer, P., Schmidli, H., and Wei, J. (2018), “Request for CHMP Qualification Opinion: Clinically Interpretable Treatment Effect Measures Based on Recurrent Event Endpoints That Allow for Efficient Statistical Analyses.”
   Google Scholar
• Anderson, R. K., and Gill, R. D. (1982), “Cox’s Regression Model for Counting Processes: A Large Sample Study,” Annals of Statistics, 10, 1100–1120.
   Web of Science ®Google Scholar
• Anker, S. D., and McMurray, J. J. V. (2012), “Time to Move on From Time-to-First: Should All Events be Included in the Analysis of Clinical Trials?” European Heart Journal, 33, 2764–2765. DOI: 10.1093/eurheartj/ehs277.
   PubMed Web of Science ®Google Scholar
• CHMP (2017), Guideline on Clinical Investigation of Medicinal Products for the Treatment of Chronic Heart Failure. EMA.
   Google Scholar
• CHMP (2020), Qualification Opinion of Clinically Interpretable Treatment Effect Measures Based on Recurrent Event Endpoints That Allow for Efficient Statistical Analyses. EMA.
   Google Scholar
• Jay, N., Cohn, M. D., and Tognoni, G. M. D. for the Valsartan Heart Failure Trial Investigators. (2001), “A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure,” New England Journal of Medicine, 345, 1667–1675. DOI: 10.1056/NEJMoa010713.
   PubMed Web of Science ®Google Scholar
• Fritsch, A., Schlömer, P., Mendolia, F., Mütze, T., Jahn-Eimermacher, A., & on behalf of the Recurrent Event Qualification Opinion Consortium (2021), “Efficiency Comparison of Analysis Methods for Recurrent Event and Time-to-First-Event Endpoints Application to Clinical Trials in Chronic Heart Failure,” Statistics in Biopharmaceutical Research, 1–11.
   Web of Science ®Google Scholar
• Ghosh, D., and Lin, D. Y. (2000), “Nonparametric Analysis of Recurrent Events and Death,” Biometrics, 56, 554–562. DOI: 10.1111/j.0006-341x.2000.00554.x.
   PubMed Web of Science ®Google Scholar
• Hernan, M. A., and Robins, J. M. (2020), Causal Inference: What If, Boca Raton: Chapman and Hall/CRC.
   Google Scholar
• ICH. (2017). “Draft ICH E9(R1) Addendum on Estimands and Sensitivity Analysis in Clinical Trials to the Guideline on Statistical Principles for Clinical Trials,” ICH.
   Google Scholar
• Lin, D.Y., Wei, L. J., Yang, I., Ying, Z. (2000), “Semiparametric Regression for the Mean and Rate Functions of Recurrent Events,” Journal of the Royal Statistical Society, Series B, 62, 711–730. DOI: 10.1111/1467-9868.00259.
   Google Scholar
• Lin, D. Y., and Wei, L. J. (1989), “The Robust Inference for the Cox Proportional Hazards Model,” Journal of American Statistical Association, 84, 1074–1078. DOI: 10.1080/01621459.1989.10478874.
   Web of Science ®Google Scholar
• Liu, L., Wolfe, R. A., and Huang, X. (2004), “Shared Frailty Models for Recurrent Events and Terminal Event,” Biometrics, 60, 219–238. DOI: 10.1111/j.0006-341X.2004.00225.x.
   Web of Science ®Google Scholar
• Mao, L., and Lin, D.Y. (2016), “Semiparametric Regression for the Weighted Composite Endpoint of Recurrent and Terminal Events,” Biostatistics, 17, 390–403. DOI: 10.1093/biostatistics/kxv050.
   PubMed Web of Science ®Google Scholar
• McCullagh, P., and Nelder, J. A. (1989), Generalized Linear Models, London: Chapman and Hall/CRC.
   Google Scholar
• McMurray, J. J., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J., Shi, V. C., Solomon, S. D., Swedberg, K., (2013), “Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients With Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF),” European Journal of Heart Failure, 15, 1062–1073. DOI: 10.1093/eurjhf/hft052.
   PubMed Web of Science ®Google Scholar
• McMurray, J. J., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J., Shi, V. C., Solomon, S. D., Swedberg, K. (2014), “Angiotensin–Neprilysin Inhibition Versus Enalapril in Heart Failure,” The New England Journal of Medicine 371, 993–1004.
   PubMed Web of Science ®Google Scholar
• Mogensen, U. M., J. Gong, P. S. Jhund, L. Shen, L. Køber, A. S. Desai, M. P. Lefkowitz, M. Packer, J. L. Rouleau, S. D. Solomon, Claggett B. L., Swedberg, K., Zile, M. R., Mueller-Velten, G., and McMurray, J.J.V. (2018), “Effect of Sacubitril/Valsartan on Recurrent Events in the Prospective Comparison of Arni with Acei to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (paradigm-hf),” European Journal of Heart Failure, 20, 760–768. DOI: 10.1002/ejhf.1139.
   PubMed Web of Science ®Google Scholar
• Ozga, A.-K., Kieser, M., Rauch, G. (2018), “A Systematic Comparison of Recurrent Event Models for Application to Composite Endpoints,” BMC Medical Research Methodology, 18, 1–12. DOI: 10.1186/s12874-017-0462-x.
   PubMed Web of Science ®Google Scholar
• Prentice, R. L., Williams, B. J., and Peterson, A. V. (1981), “On the Regression Analysis of Multivariate Failure Time Data,” Biometrika, 68, 373–379. DOI: 10.1093/biomet/68.2.373.
   Web of Science ®Google Scholar
• Rauch, G., Rauch, B., Schüler, S., and Kieser, M. (2015), “Opportunities and Challenges of Clinical Trials in Cardiology Using Composite Primary Endpoints,” World Journal of Cardiology, 26, 1–5. DOI: 10.4330/wjc.v7.i1.1.
   Google Scholar
• Roger, J., Bratton, D., Mayer, B., Abellan, J., Keene, O. (2019), “Treatment Policy Estimands for Recurrent Event Data Using Data Collected After Cessation of Randomised Treatment,” Pharmaceutical Statistics, 18, 85–95. DOI: 10.1002/pst.1910.
   PubMed Web of Science ®Google Scholar
• Rogers, J. K., Pocock, S. J., McMurray, J. J. V., Granger, C. B., Michelson, E. L., Östergren, J., Pfeffer, M. A., Solomon, S. D., Swedberg, K., Yusuf, S. (2014), “Analysing Recurrent Hospitalizations in Heart Failure: A Review of Statistical Methodology, With Application to CHARM-Preserved,” European Journal of Heart Failure, 16, 33–40. DOI: 10.1002/ejhf.29.
   PubMed Web of Science ®Google Scholar
• Rogers, J. K., Yaroshinsky, A., Pocock, S. J., Stokar, D., Pogoda, J. (2016), “Analysis of Recurrent Events With an Associated Informative Dropout Time: Application of the Joint Frailty Model,” Statistics in Medicine, 35, 2195–205. DOI: 10.1002/sim.6853.
   PubMed Web of Science ®Google Scholar
• Rufibach, K. (2019), “Treatment Effect Quantification for Time-to-Event Endpoint - Estimands, Analysis Strategies, and Beyond,” Pharmaceutical Statistics, 18, 145–169. DOI: 10.1002/pst.1917.
   PubMed Web of Science ®Google Scholar
• Schmidli, H., Roger, J., Akacha, M. (2021), “Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event,” Statistics in Biopharmaceutical Research, 1–11.
   Web of Science ®Google Scholar
• Unkel, S., Amiri, M., Benda, N., Beyersmann, J., Knoerzer, D., Kupas, K., Langer, F., Leverkus, F., Loos, A., Ose, C., Proctor, T., Schmoor, C., Schwenke, C., Skipka, G., Unnebrink, K., Voss, F., Friede, T. (2019), “On Estimands and the Analysis of Adverse Events in the Presence of Varying Follow-Up Times Within the Benefit Assessment of Therapies,” Pharmaceutical Statistics, 18, 166–183. DOI: 10.1002/pst.1915.
   PubMed Web of Science ®Google Scholar
• Wei, L., Lin, D. Y., and Weissfeld, L. (1989), “Regression Analysis of Multivariate Incomplete Failure Time Data by Modeling Marginal Distributions,” Journal of American Statistical Association, 84, 1065–1073. DOI: 10.1080/01621459.1989.10478873.
   Web of Science ®Google Scholar
• Wood, S. N. (2017), Generalized Additive Models: An Introduction With R, Boca Raton: Chapman and Hall/CRC.
   Google Scholar